1974: ISOCHEM created in Gennevilliers
1977: Pithiviers (ex. Agrifarm) site opened
1979: first U.S. Food and Drug Administration (FDA) audit and approval; export market development
1990: ISOCHEM joins Groupe SNPE
1991: ISOCHEM acquires Vert-le-Petit site (ex IRCHA Fine Chemicals and Propeptide)
2003: acquisition of the Pont-de-Claix platform and the Hungarian subsidiary Framochem
2010: acquisition of ISOCHEM by the German industrial holding company Aurelius AG
2012: acquisition of Wychem company (UK)
2014: sale of Framochem subsidiary
Initially specialized in the extraction and hemisynthesis of natural substances such as quinine, ISOCHEM has gradually expanded its expertise in multi-step industrial production encompassing a variety of operations including Grignard, Friedel-Crafts, Sandmeyer, Vilsmeier-Haack reaction, deprotonation using butyllithium, reduction using metal hydrides and hydrogenation.
In the 1990s, synergies with Groupe SNPE enabled ISOCHEM to implement new technologies such as phosgenation, nitration and manufacture of amino-acid derivatives like NCAs, UNCAs and peptides.